This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2001 Jun 9;322(7299):1379-80.

doi: 10.1136/bmj.322.7299.1379.

Drug treatment for obesity. We need more studies in men at higher risk of coronary events

PMID: 11397730
PMCID: PMC1120461
DOI: 10.1136/bmj.322.7299.1379

Editorial

Drug treatment for obesity. We need more studies in men at higher risk of coronary events

J P Després. BMJ. 2001.

. 2001 Jun 9;322(7299):1379-80.

doi: 10.1136/bmj.322.7299.1379.

Author

PMID: 11397730
PMCID: PMC1120461
DOI: 10.1136/bmj.322.7299.1379

No abstract available

PubMed Disclaimer

Comment in

Drugs are not best for obesity.
Berry EM. Berry EM. BMJ. 2001 Sep 8;323(7312):576. doi: 10.1136/bmj.323.7312.576. BMJ. 2001. PMID: 11573499 Free PMC article. No abstract available.

Similar articles

Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon?
von Haehling S, Lainscak M, Anker SD. von Haehling S, et al. Eur Heart J. 2007 Dec;28(23):2830-1. doi: 10.1093/eurheartj/ehm493. Epub 2007 Nov 5. Eur Heart J. 2007. PMID: 17984134 No abstract available.
Obesity, cardiovascular risk and pharmacotherapy.
Ruilope LM, Garcia-Robles R, Moreno B. Ruilope LM, et al. Blood Press. 2002;11(5):260-2. doi: 10.1080/080370502320779458. Blood Press. 2002. PMID: 12458647 Review. No abstract available.
Drug therapy for management of obesity.
Heine RJ. Heine RJ. Lancet. 2001 Apr 21;357(9264):1287-8. doi: 10.1016/S0140-6736(00)04425-1. Lancet. 2001. PMID: 11421206 No abstract available.
Orlistat and sibutramine beyond weight loss.
Mannucci E, Dicembrini I, Rotella F, Rotella CM. Mannucci E, et al. Nutr Metab Cardiovasc Dis. 2008 Jun;18(5):342-8. doi: 10.1016/j.numecd.2007.03.010. Epub 2007 Oct 24. Nutr Metab Cardiovasc Dis. 2008. PMID: 17928208
The use of sibutramine in the management of obesity and related disorders: an update.
Tziomalos K, Krassas GE, Tzotzas T. Tziomalos K, et al. Vasc Health Risk Manag. 2009;5(1):441-52. doi: 10.2147/vhrm.s4027. Vasc Health Risk Manag. 2009. PMID: 19475780 Free PMC article. Review.

See all similar articles

Cited by

Drugs are not best for obesity.
Berry EM. Berry EM. BMJ. 2001 Sep 8;323(7312):576. doi: 10.1136/bmj.323.7312.576. BMJ. 2001. PMID: 11573499 Free PMC article. No abstract available.
CB1 antagonists for obesity--what lessons have we learned from rimonabant?
Di Marzo V, Després JP. Di Marzo V, et al. Nat Rev Endocrinol. 2009 Nov;5(11):633-8. doi: 10.1038/nrendo.2009.197. Nat Rev Endocrinol. 2009. PMID: 19844251
Adult obesity and growth in childhood.
Law C. Law C. BMJ. 2001 Dec 8;323(7325):1320-1. doi: 10.1136/bmj.323.7325.1320. BMJ. 2001. PMID: 11739206 Free PMC article. No abstract available.
Adiponectin: An Indicator for Metabolic Syndrome.
Yosaee S, Khodadost M, Esteghamati A, Speakman JR, Djafarian K, Bitarafan V, Shidfar F. Yosaee S, et al. Iran J Public Health. 2019 Jun;48(6):1106-1115. Iran J Public Health. 2019. PMID: 31341853 Free PMC article.

References

1. James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet. 2000;356:2119–2125. - PubMed
1. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, et al. Sibutramine produces dose-related weight loss. Obes Res. 1999;7:189–198. - PubMed
1. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med. 1984;76:4–12. - PubMed
1. Resin E, Abel R, Modan M, Silverberg DS, Eliahou HE, Modan B. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med. 1978;298:1–6. - PubMed
1. Reaven GR, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374–381. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information